Fredun Pharmaceuticals Ltd (FREDUN) — Board Meeting | 16 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board allotted 271,200 equity shares to non-promoter warrant holders upon conversion.
🔄 What Changed
271,200 shares allotted; 90,400 warrants converted; total outstanding warrants now 37,600.
💡 Investor Takeaway
Share dilution may pressure stock price as new shares enter the market.

On September 16, 2026, Fredun Pharmaceuticals' board allotted 271,200 equity shares of Rs 10 each to non-promoter warrant holders following conversion of 90,400 warrants, completing a process approved by shareholders in October 2025; the shares were issued in dematerialized form and rank pari passu with existing shares.

📄 View Original Announcement (PDF)

About Fredun Pharmaceuticals Ltd (FREDUN)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹2,020.29 Cr P/E: 14.3 ROE: 16.6% ROCE: 20.5% Div Yield: 0.06%

View full FREDUN stock details →

📡 Get AI alerts when FREDUN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FREDUN — Free

📊 More FREDUN filings

See all FREDUN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FREDUN files new disclosures

Track FREDUN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FREDUN — Free

Free account · 2 AI queries/day